Key Insights

Highlights

Success Rate

89% trial completion (above average)

Published Results

44 trials with published results (11%)

Research Maturity

156 completed trials (39% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

5.0%

20 terminated out of 403 trials

Success Rate

88.6%

+2.1% vs benchmark

Late-Stage Pipeline

5%

22 trials in Phase 3/4

Results Transparency

28%

44 of 156 completed with results

Key Signals

44 with results89% success20 terminated

Data Visualizations

Phase Distribution

250Total
Not Applicable (112)
Early P 1 (3)
P 1 (39)
P 2 (74)
P 3 (14)
P 4 (8)

Trial Status

Completed156
Recruiting82
Unknown77
Active Not Recruiting31
Not Yet Recruiting26
Terminated20

Trial Success Rate

88.6%

Benchmark: 86.5%

Based on 156 completed trials

Clinical Trials (403)

Showing 20 of 20 trials
NCT06991738Phase 1Not Yet RecruitingPrimary

177Lu-DOTA-EB-TATE in Adult Patients With Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer

NCT02747888Not ApplicableRecruitingPrimary

Hereditary Risk Factors for Thyroid Cancer

NCT05538130Phase 1Recruiting

A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors

NCT07634978Not ApplicableRecruitingPrimary

Development and Application of an AI Chatbot for Perioperative Health Education in Thyroid Cancer Patients

NCT03196518Not ApplicableActive Not RecruitingPrimary

Study of PET Imaging With 18F-TFB in Patients With Thyroid Cancer

NCT03841617Phase 2RecruitingPrimary

The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer

NCT05355701Phase 1Recruiting

A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.

NCT07225309Not ApplicableNot Yet Recruiting

A Study of Meaning-Centered Therapy for Mexican Adults With Advanced Cancer

NCT04566393Unknown

Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies

NCT04285476Not ApplicableActive Not RecruitingPrimary

Predictive Value of microRNA in Thyroid Cytologies of Undetermined Type

NCT04104529Not ApplicableRecruitingPrimary

Clinico-biological Database in Patients Treated With Metabolic Radiotherapy in the Nuclear Medicine Department

NCT07623005Not ApplicableCompletedPrimary

Progressive Muscle Relaxation for Pain and Quality of Life in Thyroid Cancer

NCT06959511Phase 2Recruiting

Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery

NCT07124000Recruiting

DESTINY-PANTUMOUR04

NCT06851663Phase 2Recruiting

Trop2-targeted immunoPET Imaging of Solid Tumors

NCT06465017Not ApplicableTerminated

ImmunoPET Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) in Thyroid Cancer

NCT07600580Phase 4Active Not RecruitingPrimary

The Association Between Bilateral Intermediate Cervical Plexus Block During Total Thyroidectomy and Surgical Stress Response

NCT06673329Phase 1Recruiting

Brodalumab in the Treatment of Immune-Related Adverse Events

NCT07524777Not ApplicableRecruiting

Ganoderma Spores Modulate the Gut-Brain Axis

NCT00001160Recruiting

Studies on Tumors of the Thyroid

Scroll to load more

Research Network

Activity Timeline